Novel therapies for chronic myelogenous leukemia

被引：34

作者：

Jahagirdar, BN ^{[1
]}

Miller, JS ^{[1
]}

Shet, A ^{[1
]}

Verfaillie, CM ^{[1
]}

机构：

[1] Univ Minnesota, Div Hematol Oncol & Transplantat, Stem Cell Inst, Minneapolis, MN 55455 USA

来源：

EXPERIMENTAL HEMATOLOGY | 2001年 / 29卷 / 05期

关键词：

D O I：

10.1016/S0301-472X(01)00633-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The BCR-ABL oncogene is essential to the pathogenesis of chronic myelogenous leukemia, and immune mechanisms play an important role in control of this disease. Understanding of the molecular pathogenesis of chronic myelogenous leukemia has led to the development of several novel therapies, which can be broadly divided into therapies based on 1) inhibition of the BCR-ABL oncogene expression, 2) inhibition of other genes important to the pathogenesis of chronic myelogenous leukemia, 3) inhibition of BCR-ABL protein function, and 4) immunomodulation, We have systematically review-ed each of these novel therapeutic approaches in this article. (C) 2001 International Society for Experimental Hematology, Published by Elsevier Science Inc.

引用

页码：543 / 556

页数：14

共 213 条

[51]

DRUKER BJ, 1999, P ASCO, V18, pA24

[52] Transduction of hematopoietic stem cells in humans and in nonhuman primates [J].

Dunbar, CE ;

Tisdale, J ;

Yu, JM ;

Soma, T ;

Zujewski, J ;

Bodine, D ;

Sellers, S ;

Cowan, K ;

Donahue, R ;

Emmons, R .

STEM CELLS, 1997, 15 :135-139

[53]

EMANUEL P, 1997, BLOOD, V92, pA567

[54] Farnesyl protein transferase inhibitors and other therapies targeting the ras signal transduction pathway [J].

End, DW .

INVESTIGATIONAL NEW DRUGS, 1999, 17 (03) :241-258

[55] Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Early transplantation use of an unrelated donor, and chronic graft-versus-host disease are protective [J].

Enright, H ;

Davies, SM ;

DeFor, T ;

Shu, X ;

Weisdorf, D ;

Miller, W ;

Ramsay, NKC ;

Arthur, D ;

Verfaillie, C ;

Miller, J ;

Kersey, J ;

McGlave, P .

BLOOD, 1996, 88 (02) :714-720

[56]

Enright H, 1996, BONE MARROW TRANSPL, V17, P537

[57]

FABER LM, 1995, BLOOD, V86, P2821

[58] Mechanisms of disease - The biology of chronic myeloid leukemia [J].

Faderl, S ;

Talpaz, M ;

Estrov, Z ;

O'Brien, S ;

Kurzrock, R ;

Kantarjian, HM .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (03) :164-172

[59] GENERATION OF DONOR-DERIVED ANTILEUKEMIC CYTOTOXIC T-LYMPHOCYTE RESPONSES FOR TREATMENT OF RELAPSED LEUKEMIA AFTER ALLOGENEIC HLA-IDENTICAL BONE-MARROW TRANSPLANTATION [J].

FALKENBURG, JHF ;

FABER, LM ;

VANDENELSHOUT, M ;

VANLUXEMBURGHEIJS, SAP ;

HOOFTMANDENOTTER, A ;

SMIT, WM ;

VOOGT, PJ ;

WILLEMZE, R .

JOURNAL OF IMMUNOTHERAPY, 1993, 14 (04) :305-309

[60] Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation [J].

Fujii, S ;

Shimizu, K ;

Fujimoto, K ;

Kiyokawa, T ;

Shimomura, T ;

Taniguchi, O ;

Kinoshita, M ;

Kawano, F .

JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (10) :1117-1129

← 1 2 3 4 5 6 7 8 9 10 →